Publication Name	World Journal of Gastroenterology
Manuscript ID	12396
Country	France

Received	2014-07-06 13:59
Peer-Review Started	2014-07-07 13:04
To Make the First Decision	2014-07-21 12:46
Return for Revision	2014-07-25 09:16
Revised	2014-07-29 15:24
Second Decision	2014-11-11 10:07
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-11-11 10:23
Articles in Press	2014-11-11 10:59
Publication Fee Transferred
Edit the Manuscript by Language Editor	2014-12-22 01:43
Typeset the Manuscript	2015-02-02 13:46
Publish the Manuscript Online	2015-02-11 16:38

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Retrospective Study
Article Title	FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma
Manuscript Source	Unsolicited Manuscript
All Author List	Jean-Florian Guion-Dusserre, Veronique Lorgis, Julie Vincent, Leila Bengrine and Francois Ghiringhelli
Funding Agency and Grant Number
Corresponding Author	Francois Ghiringhelli, MD, PhD, Department of Medical Oncology, Centre Georges-François Leclerc, INSERM Avenir 866, 1 rue du Professeur Marion, 21000 Dijon, France. fghiringhelli@cgfl.fr
Key Words	Biliary tract cancer; Intrahepatic cholan­giocarcinoma; FOLFIRI; Bevacizumab; Second-line treatment
Core Tip	This retrospective study tests the efficacy of FOLFIRI plus bevacizumab as second-line treatment for metastatic cholangiocarcinoma. We observed that this particular chemotherapy treatment gives good response rates and prolongs survival.
Publish Date	2015-02-11 16:38
Citation	Guion-Dusserre JF, Lorgis V, Vincent J, Bengrine L, Ghiringhelli F. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. World J Gastroenterol 2015; 21(7): 2096-2101
URL	http://www.wjgnet.com/1007-9327/full/v21/i7/2096.htm
DOI	http://dx.doi.org/10.3748/wjg.v21.i7.2096

Full Article (PDF)	WJG-21-2096.pdf
Full Article (Word)	WJG-21-2096.doc
Manuscript File	12396-Review.doc
Answering Reviewers	12396-Answering reviewers.pdf
Copyright License Agreement	12396-Copyright assignment.pdf
Peer-review Report	12396-Peer reviews.pdf
Scientific Misconduct Check	12396-CrossCheck.jpg
Scientific Editor Work List	12396-Scientific editor work list.pdf